All articles by
Coherus Completes Surface Oncology Acquisition
Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance next-generation immuno-oncology portfolio focused on the tumor microenvironment
Valneva, Pfizer’s VLA15 shows positive paediatric, adolescent Phase 2 booster results
These findings from the VLA15-221 Phase 2 study demonstrated a strong anamnestic antibody response for all serotypes in paediatric and adolescents as well as in adults one month after the administration of a booster dose
NICE committee approves Tirzepatide for type 2 diabetes treatment
According to data from clinical trials, Tirzepatide was significantly more effective at lowering blood sugar levels and body weight than semaglutide, insulin treatment, or a placebo
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placebo
Janssen’s Rybrevant combination therapy meets primary endpoint in Phase 3 lung cancer study
In the study, the therapy showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy alone in both experimental treatment arms
Thoma Bravo agrees to acquire NextGen Healthcare
The transaction is poised to accelerate NextGen Healthcare’s growth and innovation, reinforcing its position as a trusted advisor to healthcare providers
Update on US regulatory review of Ultomiris in NMOSD
The CRL did not request additional analysis or reanalysis of the Phase III CHAMPION-NMOSD trial data included in the sBLA submission and did not raise concerns about the efficacy or safety data from the trial
Moderna Clinical Trial Data Confirm Its Updated Covid-19 vaccine generates strong immune response in humans against BA.2.86
CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 vaccine for the fall 2023 season
Mirum acquires Travere’s Cholbam and Chenodal bile acid products
As per the terms of the agreement announced in July, Travere Therapeutics remains entitled to receive potential milestone payments based on sales, with a total potential value of up to $235m
MHRA approves Pfizer/BioNTech’s adapted COVID-19 vaccine that targets Omicron XBB.1.5
The vaccine was approved after it was found to meet the UK regulator’s standards of safety, quality and effectiveness